Enliven Therapeutics Inc (NAS:ELVN)
$ 20.44 -0.49 (-2.34%) Market Cap: 961.43 Mil Enterprise Value: 664.23 Mil PE Ratio: 0 PB Ratio: 3.08 GF Score: 22/100

Enliven Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 03:00PM GMT
Release Date Price: $22.73 (-0.09%)
Eun Yang
(Trades, Portfolio) LLC - Analyst

This is Eun Yang, a biotech analyst with the Jefferies. Next presenting company is Enliven. And presenting from Enliven is Sam Kintz, CEO of the company. Sam?

Sam Kintz
Enliven Therapeutics, Inc - Co-Founder, CEO, & Board Member

Hello, everyone. Okay. I'll just start with a 30,000-foot introduction of our company. And so in brief, we're early clinical stage precision oncology company. Our primary focus really is validated biology, validated targets, and pursuing those targets with differentiated chemistry really aimed at addressing both new and evolving emerging unmet needs.

We have two parallel lead programs, as I mentioned, both early clinical stage and both targeted -- validated cancer targets,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot